The Bioprocessing Summit

Cambridge Healthtech Institute’s 6th Annual
Optimizing Cell Line Development
Enhancing Expression
Part of CHI’s 6th Annual The Bioprocessing Summit

August 21-22, 2014 | Renaissance Waterfront Hotel | Boston, Massachusetts

The “Optimizing Cell Line Development” meeting features experts sharing their case studies and anecdotes that illustrate the strategies they use to reach enhanced expression and lower costs.  Their research and experiences provide meaningful insights into how to best select cell lines and hosts, and develop high-producers into late-stage production.  Gaining a greater understanding of cells through sequencing and the omic sciences will also be addressed, including the CHO genome research, metabolomics, assays, and QPCR.  In addition, challenges for introducing new technologies will be discussed, along with an overview of industrial trends and regulatory perspectives.

Day 1 | Day 2 | Short Courses | Download Brochure | Speaker Bios

Suggested Short Course*

Bioprocess Development: Considerations for the Quality and Safety of Materials in Contact with Biologics 

Thursday, August 21, 6:30-9:00 pm

*Separate registration required

Thursday, August 21


1:55 pm Chairperson’s Remarks

Jesús Zurdo, Ph.D., Head, Innovation, Biopharma Development, Lonza Biologics plc


Moving Beyond the Off-the-Shelf CHO Host to New Improved Expression Hosts

Scott EstesScott Estes, Ph.D., Director, Cell Culture Development, Biogen Idec, Inc.

CHO does not have a dedicated secretory phenotype and may be ill-equipped to handle the elevated secretory load incurred during the production of biologics. To facilitate a rational selection of candidate targets, we mined published genome wide screens to identify key regulators of secretion. These targets were overexpressed in CHO cells and the resulting engineered hosts studied to determine their ability to express mAbs. Of the fourteen genes investigated, we identified one, a small GTP-binding protein, which significantly improved productivity.

2:45 Full Transcriptome Analysis of Chinese Hamster Ovary Cell Lines Producing a Dynamic Range of Coagulation Factor VIII

Christian Schrøder KaasChristian Schrøder Kaas, Ph.D., Researcher, Mammalian Cell Technology, Novo Nordisk A/S

Coagulation Factor VIII (FVIII) is an important biopharmaceutical for treating haemophilia A. Yields of FVIII produced in Chinese Hamster Ovary cells are low and thus a better understanding of what constitute a high producing cell line is desired. In this study a full transcriptome analysis was undertaken to analyse a series of CHO cell lines producing different levels of FVIII. The initial aim is to pinpoint the differences between high and low producers of FVIII and eventually this information may be used to engineer better production cell lines.

3:15 Optimization of the CHEF1 CHO Expression Platform

Howard ClarkeHoward Clarke, Ph.D., Director, Upstream Process Development, CMC Biologics

The Chinese Hamster Elongation Factor 1a (CHEF1) platform is designed for the manufacture of recombinant therapeutic proteins in stable CHO cells using chemically defined media. CHEF1 expression has been shown to improve yield over CMV-controlled plasmids in CHO cells and is associated with growth, such that titer increases with volumetric productivity. Recent integration of CMV regulatory domains into the CHEF1 plasmid has led to increased productivity in the later-stage process, increasing production duration and overall yield.

3:45 Innovative Simulation Technologies to Optimize Cell Culture

Marc Horner PhDMarc Horner, Ph.D., Lead Technical Services Engineer, ANSYS, Inc.

Cell culture is a delicate process in which cell growth and occasionally cell damage are influenced by flow conditions. Engineering simulation and CFD are used to investigate the transient flow behavior in bioreactors. ANSYS experts discuss how influential parameters affect the flow pattern and hence the evolution of cell culture. This insight opens the door to simulation based process optimization.

4:00 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Targeted Integration of “Hotspots” in CHO Genome for Rapid Generation of Stable and High Monoclonal Antibody Producing Cell Lines

Yuansheng YangYuansheng Yang, Ph.D., Research Scientist, Animal Cell Technology, Bioprocessing Technology Institute

Targeted integration into hotspots for cell line development is attractive for rapid generation of cell lines with stable and high productivity. Converting the concept to practical application is very challenging. We established protocols for generation of master clones with hotspots tagged with a vector carrying site specific recombinase recognition sequence. The master clones allowed rapid generation of monoclonal antibody producing cell lines with high and stable productivity.

5:15 CHippO: Manipulation of the Hippo Signaling Pathway in CHO to Produce a Superior Host for Recombinant Protein Expression

John FollitJohn Follit, Ph.D., Scientist I, Cell Line Technology, Biogen Idec, Inc.

The Hippo signaling pathway controls cell proliferation and organ size by activating Yes-associated protein 1 (Yap1). We hypothesized that altering the Hippo pathway may result in an engineered host cell with an improved bioprocessing phenotype. To this end, we created Yap1 overexpressing CHO cells (CHippO) and auditioned the new host with model monoclonal antibodies. CHippO cells exhibited significant boosts in mAb expression with top clones from the engineering CHIPPO host achieving titers up to three times higher than clones arising from an unmodified host.

5:45 End of Day

5:45-6:30 Dinner Short Course Registration

6:30-9:00 Bioprocess Development: Considerations for the Quality and Safety of Materials in Contact with Biologics *

*Separate registration required

Day 1 | Day 2 | Short Courses | Download Brochure | Speaker Bios